This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Protein phosphatase 1 regulatory subunit 3C (PPP1R3C; PTG); epilepsy progressive myoclonus type 2A Lafora disease (laforin; EPM2A); NHL repeat containing 1 (NHLRC1; EPM2B)	<p>Studies in mice suggest inhibiting PTG could help treat Lafora disease, a teenage onset epilepsy disorder caused by <i>EPM2A</i> or <i>EPM2B</i> mutations. <i>Epm2a</i> and <i>Ptg</i> double knockout mice had fewer seizures and Lafora bodies in the brain and less neurodegeneration than <i>Epm2a</i> single knockout mice. Future studies could include identifying PTG inhibitors.</p> <p>SciBX 4(20); doi:10.1038/scibx.2011.580 Published online May 19, 2011</p>	Unpatented; unlicensed	<p>Turnbull, J. <i>et al. PLoS Genet.</i>; published online April 28, 2011; doi:10.1371/journal.pgen.1002037 Contact: Berge A. Minassian, The Hospital for Sick Children, Toronto, Ontario, Canada e-mail: berge.minassian@sickkids.ca Contact: Anna A. DePaoli-Roach, Indiana University, Indianapolis, Ind. e-mail: adepaoli@iupui.edu</p>